Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B

Full story: https://grafa.com/en/news/united-states/merck-q3-2026-revenue-rises-5-percent

Key points

Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, and adjusted earnings per share of $2.49, above the $2.09 analyst consensus.
Keytruda sales, including Keytruda Qlex, reached $8.6 billion, while Winrevair sales climbed 93% to $694 million.
Merck increased its 2026 adjusted EPS guidance to $2.77–$2.82 per share and narrowed its revenue outlook to $66.8 billion–$67.3 billion.

Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, as growth in key pharmaceutical products supported results.

The company beat analyst expectations and raised its full-year adjusted profit outlook.

GAAP net income reached $5.07 billion, equivalent to $2.04 per share.

Adjusted earnings per share, which excludes certain items, increased to $2.49, exceeding the analyst consensus of $2.09.

Keytruda, including Keytruda Qlex, generated $8.6 billion in sales, up 6% year over year.

The subcutaneous formulation Keytruda Qlex contributed $830 million.

Winrevair sales increased 93% to $694 million, while Gardasil and Gardasil 9 generated approximately $2 billion in sales, up 14% excluding foreign exchange effects.

Animal Health revenue rose 4% to $1.7 billion.

Looking ahead, Merck raised its full-year 2026 adjusted EPS guidance to $2.77–$2.82 per share, from the previous range of $2.66–$2.76.

The revised outlook includes a one-time charge of $0.12 per share related to a licensing agreement with SciBrunch.

The company also narrowed its full-year revenue guidance to $66.8 billion–$67.3 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":623911969477232,"tweetId":"623911969477232","gmtCreate":1793337691007,"gmtModify":1793337699909,"author":{"id":4169784042383112,"idStr":"4169784042383112","authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":259,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/cbd86e1e75bb9f69d48735d7dca98dae","width":"1672","height":"941"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/cbd86e1e75bb9f69d48735d7dca98dae","width":"1672","height":"941"}],"title":"Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/cbd86e1e75bb9f69d48735d7dca98dae\" tg-width=\"1672\" tg-height=\"941\"></p>\n<p>Full story: https://grafa.com/en/news/united-states/merck-q3-2026-revenue-rises-5-percent</p>\n<h2>Key points</h2>\n<ul>\n <li>\n  <p>Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, and adjusted earnings per share of $2.49, above the $2.09 analyst consensus.</p></li>\n <li>\n  <p>Keytruda sales, including Keytruda Qlex, reached $8.6 billion, while Winrevair sales climbed 93% to $694 million.</p></li>\n <li>\n  <p>Merck increased its 2026 adjusted EPS guidance to $2.77–$2.82 per share and narrowed its revenue outlook to $66.8 billion–$67.3 billion.</p></li>\n</ul>\n<p>Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, as growth in key pharmaceutical products supported results.</p>\n<p>The company beat analyst expectations and raised its full-year adjusted profit outlook.</p>\n<p>GAAP net income reached $5.07 billion, equivalent to $2.04 per share.</p>\n<p>Adjusted earnings per share, which excludes certain items, increased to $2.49, exceeding the analyst consensus of $2.09.</p>\n<p>Keytruda, including Keytruda Qlex, generated $8.6 billion in sales, up 6% year over year.</p>\n<p>The subcutaneous formulation Keytruda Qlex contributed $830 million.</p>\n<p>Winrevair sales increased 93% to $694 million, while Gardasil and Gardasil 9 generated approximately $2 billion in sales, up 14% excluding foreign exchange effects.</p>\n<p>Animal Health revenue rose 4% to $1.7 billion.</p>\n<p>Looking ahead, Merck raised its full-year 2026 adjusted EPS guidance to $2.77–$2.82 per share, from the previous range of $2.66–$2.76.</p>\n<p>The revised outlook includes a one-time charge of $0.12 per share related to a licensing agreement with SciBrunch.</p>\n<p>The company also narrowed its full-year revenue guidance to $66.8 billion–$67.3 billion.</p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/cbd86e1e75bb9f69d48735d7dca98dae\" tg-width=\"1672\" tg-height=\"941\"></p>\n<p>Full story: https://grafa.com/en/news/united-states/merck-q3-2026-revenue-rises-5-percent</p>\n<h2>Key points</h2>\n<ul>\n <li>\n  <p>Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, and adjusted earnings per share of $2.49, above the $2.09 analyst consensus.</p></li>\n <li>\n  <p>Keytruda sales, including Keytruda Qlex, reached $8.6 billion, while Winrevair sales climbed 93% to $694 million.</p></li>\n <li>\n  <p>Merck increased its 2026 adjusted EPS guidance to $2.77–$2.82 per share and narrowed its revenue outlook to $66.8 billion–$67.3 billion.</p></li>\n</ul>\n<p>Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, as growth in key pharmaceutical products supported results.</p>\n<p>The company beat analyst expectations and raised its full-year adjusted profit outlook.</p>\n<p>GAAP net income reached $5.07 billion, equivalent to $2.04 per share.</p>\n<p>Adjusted earnings per share, which excludes certain items, increased to $2.49, exceeding the analyst consensus of $2.09.</p>\n<p>Keytruda, including Keytruda Qlex, generated $8.6 billion in sales, up 6% year over year.</p>\n<p>The subcutaneous formulation Keytruda Qlex contributed $830 million.</p>\n<p>Winrevair sales increased 93% to $694 million, while Gardasil and Gardasil 9 generated approximately $2 billion in sales, up 14% excluding foreign exchange effects.</p>\n<p>Animal Health revenue rose 4% to $1.7 billion.</p>\n<p>Looking ahead, Merck raised its full-year 2026 adjusted EPS guidance to $2.77–$2.82 per share, from the previous range of $2.66–$2.76.</p>\n<p>The revised outlook includes a one-time charge of $0.12 per share related to a licensing agreement with SciBrunch.</p>\n<p>The company also narrowed its full-year revenue guidance to $66.8 billion–$67.3 billion.</p></body></html>","text":"Full story: https://grafa.com/en/news/united-states/merck-q3-2026-revenue-rises-5-percent Key points Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, and adjusted earnings per share of $2.49, above the $2.09 analyst consensus. Keytruda sales, including Keytruda Qlex, reached $8.6 billion, while Winrevair sales climbed 93% to $694 million. Merck increased its 2026 adjusted EPS guidance to $2.77–$2.82 per share and narrowed its revenue outlook to $66.8 billion–$67.3 billion. Merck (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year, as growth in key pharmaceutical products supported results. The company beat analyst expectations and raised its full-year adjusted profit outlook. GAAP net income reached $5.07 billion, equivalent to $2.04 per share. Adjusted earnings per share, which excludes certain items, increased to $2.49, exceeding the analyst consensus of $2.09. Keytruda, including Keytruda Qlex, generated $8.6 billion in sales, up 6% year over year. The subcutaneous formulation Keytruda Qlex contributed $830 million. Winrevair sales increased 93% to $694 million, while Gardasil and Gardasil 9 generated approximately $2 billion in sales, up 14% excluding foreign exchange effects. Animal Health revenue rose 4% to $1.7 billion. Looking ahead, Merck raised its full-year 2026 adjusted EPS guidance to $2.77–$2.82 per share, from the previous range of $2.66–$2.76. The revised outlook includes a one-time charge of $0.12 per share related to a licensing agreement with SciBrunch. The company also narrowed its full-year revenue guidance to $66.8 billion–$67.3 billion.","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/623911969477232","repostId":0,"isVote":1,"tweetType":1,"viewCount":14,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1431,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/623911969477232"}